N
LABP

Nuveen’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Nuveen’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,022
Closed -$118K – 3459
2021
Q2 		$118K Hold
1,022
– – ﹤0.01% 3269
2021
Q1 		$98K Buy
+1,022
New +$133K ﹤0.01% 3290

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $420M AUM 42.19% 1-Year Est. Return

Nuveen's LABP Position: Q3 2021 in Review

Nuveen sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q3 2021, closing a stake of 1,022 shares — an estimated $118K sold.

Nuveen first reported a position in LABP in Q1 2021 and held it in 2 quarters. The position peaked at $118K in Q2 2021. 35 funds tracked by Wall St. Rank hold LABP as of Q3 2021.

  • Nuveen reported no remaining Landos Biopharma, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Nuveen sold 1,022 Landos Biopharma, Inc. Common Stock shares in Q3 2021, an estimated $118K.
  • Nuveen first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Nuveen's Landos Biopharma, Inc. Common Stock position peaked at $118K in Q2 2021.
  • 35 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q3 2021.

Based on Nuveen's 13F filing for Q3 2021, filed 12 Nov 2021.